Human epidermal growth factor receptor 2 (HER-2), as a crucial factorinvolved in about 20% of breast cancer cases, is one of the most reliable tumor markersto determine prognosis and therapeutic trend of this disease. This evidence concerns the gene ERBB2 and breast carcinoma.